GSK gains European approval for epilepsy drug

As reported by The Pharma Times, GlaxoSmithKline (GSK) gained European approval for their epilepsy drug, Trobalt.

The drug is unique in that it acts faster than existing treatments, taking effect as little as 90 minutes after being taken. It is designed to help suffers of epilepsy gain greater control over their seizures.

European approval for the drug came as a result of two pivotal phase 2 studies. These studies highlighted a significant improvement in seizure control, with patients experiencing on average, 50% less seizures when compared to the placebo.

Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.

Posted in: Industry News
CK Logo in place of featured image